Trial reportWorld journal of gastroenterology2007
Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial.
Trial report in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Antioxidant supplements for liver diseases.The Cochrane database of systematic reviews · 2011Pooled it
- Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C.World journal of gastroenterology · 2010Trial
- Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review.Archives of microbiology · 2023Review
- Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants.American journal of translational research · 2023Review
- The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Antiviral Activities of Silymarin and Derivatives.Molecules (Basel, Switzerland) · 2019Review
- Review
- Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.World journal of gastroenterology · 2016Review
- Silymarin in the treatment of liver diseases: What is the clinical evidence?Clinical liver disease · 2016Article
- Oxidative stress modulation in hepatitis C virus infected cells.World journal of hepatology · 2015Review
- Cell death and cell death responses in liver disease: mechanisms and clinical relevance.Gastroenterology · 2014Review
- Complementary and alternative medications in hepatitis C infection.World journal of hepatology · 2014Review
- An insight into the diagnosis and pathogenesis of hepatitis C virus infection.World journal of gastroenterology · 2013Review
- Antioxidants as therapeutic agents for liver disease.Liver international : official journal of the International Association for the Study of the Liver · 2011Review
- Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention.The Journal of surgical research · 2011Review
- An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.World journal of gastroenterology · 2010Article
- Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress.Viruses · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the safety and efficacy of antioxidant therapy for patients with chronic hepatitis C virus (HCV) infection.
methodsOne hundred chronic HCV infection patients failed in interferon treatment were enrolled and randomly assigned to receive combined intravenous and oral antioxidants or placebo, or oral treatment alone. Primary end points were liver enzymes, HCV-RNA levels and histology.
resultsCombined oral and intravenous antioxidant therapy was associated with a significant decline in ALT levels in 52% of patients who received antioxidant therapy vs 20% of patients who received placebo (P = 0.05). Histology activity index (HAI) score at the end of treatment was reduced in 48% of patients who received antioxidant therapy vs 26% of patients who received placebo (P = 0.21). HCV-RNA levels decreased by 1-log or more in 28% of patients who received antioxidant therapy vs 12% who received placebo (P = NS). In part II of the trial, oral administration of antioxidants was not associated with significant alterations in any of the end points.
conclusionAntioxidant therapy has a mild beneficial effect on the inflammatory response of chronic HCV infection patients who are non-responders to interferon. Combined antiviral and antioxidant therapy may be beneficial for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.